[ad_1]
As the world awaits the date of the emergence of the vaccine that will end the ongoing epidemic in its crop in various countries, recording second and third waves in many of them, Andrew Pollard, head of the management of the working group on the Covid 19 vaccine trial which is being led by the University of Oxford in Great Britain in partnership with the Anglo-Swedish company AstraZeneca Wednesday, to a slight possibility that the vaccine will be launched before the end of December.
He also said in press releases that the final results of the vaccine trials will be tentatively presented before the end of this year.
Asked about the possibility of launching the vaccine before December 24, he replied: “There is a small chance”.
Back … and previous stop
It is worth noting that this vaccine suffered a setback last month with the death of a Brazilian volunteer during clinical trials, as the British University confirmed that testing of the “AstraZeneca and Oxford” vaccine will continue even after the death of the volunteer, which will be studied with his circumstances, while observers considered that his death would constitute a major setback for the vaccine if it were indeed proven. Linked to experiences.
Previously, final clinical trials for this vaccine were also temporarily halted at the beginning of last September, after a volunteer fell ill in Britain, and “AstraZeneca” described it at that time as a “procedure. routine “which takes place in the event that a participant suffers from an” uncertain illness “. The results of the trials are being followed closely all over the world.
There was high hope that this vaccine would be the first to hit the market in terms of vaccines, after successful first and second stage testing, while around 30,000 participants in the phase 3 transition participated in the United States. United Kingdom, Brazil and South Africa.
Source link
